Early interim FDG PET/CT prediction of treatment response and prognosis in pediatric Hodgkin disease - Added value of low-dose CT

Pediatric Radiology

Volumn 43, Issue 1, 2013, Pages 86-92

  Ilivitzki, Anat ^a   Radan, Lea ^a   Ben Arush, Miriam ^a   Israel, Ora ^a   Ben Barak, Ayelet ^a  

^a Rambam Health Care Campus ^*  (Israel)

Author keywords

ALARA; Hodgkin disease; Interim PET CT; Pediatric malignancy

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; CANCER PROGNOSIS; CANCER RECURRENCE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONFERENCE PAPER; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MALE; OUTCOME ASSESSMENT; PREDICTION; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE; SCHOOL CHILD; TREATMENT RESPONSE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RADIATION DOSAGE; RADIOPHARMACEUTICALS;

EID: 84872679068     PISSN: 03010449     EISSN: 14321998     Source Type: Journal    
DOI: 10.1007/s00247-012-2517-9     Document Type: Conference Paper

References (24)

1. Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586
2. Juweid ME, Stroobants S, Hoekstra OS et al (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol 25:571-578
3. Hoekstra OS, Ossenkoppele GJ, Golding R et al (1993) Early treatment response in malignant lymphoma, as determined by planar fluorine-18- fluorodeoxyglucose scintigraphy. J Nucl Med 34:1706-1710
4. Kostakoglu L, Coleman M, Leonard JP et al (2002) PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 43:1018-1027
5. Torizuka T, Nakamura F, Kanno T et al (2004) Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 31:22-28
6. Hutchings M, Mikhaeel NG, Fields PA et al (2005) Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 16:1160-1168
7. Hutchings M, Loft A, Hansen M et al (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52-59
8. Zinzani PL, Tani M, Fanti S et al (2006) Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol 17:1296-1300
9. Gallamini A, Rigacci L, Merli F et al (2006) The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 91:475-481
10. Gallamini A, Hutchings M, Rigacci L et al (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25:3746-3752
11. Furth C, Steffen IG, Amthauer H et al (2009) Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial. J Clin Oncol 27:4385-4391
12. Bar-Sever Z, Keidar Z, Ben-Barak A et al (2007) The incremental value of 18F-FDG PET/CT in paediatric malignancies. Eur J Nucl Med Mol Imaging 34:630-637
13. Keller FG, Castellino SM, Nachman JB (2009) What is the best treatment for children with limited-stage Hodgkin lymphoma? Curr Hematol Malig Rep 4:129-135
14. Mauz-Körholz C, Hasenclever D, Dörffel W et al (2010) Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol 28:3680-3686
15. Borchmann P, Diehl V, Engert A (2011) ABVD versus BEACOPP for Hodgkin's lymphoma. N Engl J Med 365:1545-1546
16. Schwartz CL, Constine LS, Villaluna D et al (2009) A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high risk Hodgkin lymphoma: the results of P9425. Blood 114:2051-2059
17. Diehl V, Franklin J, Pfreundschuh M et al (2003) Standard and increased dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386-2395
18. Cheson BD, Pfistner B, Juweid ME (1999). Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. NCI Sponsored International Workshop Group. J Clin Oncol 1244-1253
19. Meany HJ, Gidvani VK, Minniti CP (2007) Utility of PET scans to predict disease relapse in pediatric patients with Hodgkin lymphoma. Pediatr Blood Cancer 48:399-402
20. Levine JM, Weiner M, Kelly KM (2006) Routine use of PET scans after completion of therapy in pediatric Hodgkin disease results in a high false positive rate. J Pediatr Hematol Oncol 28:711-714
21. Miller E, Metser U, Avrahami G et al (2006) Role of 18F-FDG PET/CT in staging and follow-up of lymphoma in pediatric and young adult patients. J Comput Assist Tomogr 30:689-694
22. MacManus MP, Seymour JF, Hicks RJ (2007) Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging 7:10-18
23. Haioun C, Itti E, Rahmouni A et al (2005) FDG-PET in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106:1376-1381
24. Hutchings M, Barrington SF (2009) PET/CT for therapy response assessment in Lymphoma. J Nucl Med 50:21s-30s